Goodwin-Led Dimension Therapeutics Preps $115M Debut
Venture capital-backed Dimension Therapeutics Inc., an early-stage developer of gene therapies for rare liver diseases counseled by Goodwin & Procter LLP, filed papers Monday for a $115 million initial public offering,...To view the full article, register now.
Already a subscriber? Click here to view full article